Introduction
Naturally occurring anti-keratin antibodies (AKA) in human sera were first noted in this laboratory by R S Lloyd in 1970 (unpublished data) using rat oesophagus tissue and fluorescent antibody techniques. The keratins are a family of intracellular, fibrous, and highly complex insoluble proteins exhibiting pronounced heterogeneity. Their structure and chemistry has been extensively studied and reviewed.' Their antigenicity was first shown experiinentally by Pillemer et al.' Later studies disclosed considerable cross-reactivity between keratins derived from both human3-5 and animal6 tissues. These differences were partially resolved by Lee et al,7 who isolated four polypeptides from the precursor protein prekeratin. These are designated A, A', B, and B' and form two immunologically distinct families of A and B chains in mixed proportions. Furthermore, antisera raised to A and B chains react with the major structural protein of the epidermis. Although these findings confirm the work of Bauer,3 Kemp and Rogers6 detected no such antigenic relation with keratins derived from differentiating cortical cells.
We now think that the antigenic specificity of the keratin molecule may be modified by reorganisation ofthe A and B chains during the keratinisation process itself; this is discussed by B J J Young (paper in preparation). Preliminary testing for AKA was carried out on 10 589 sera from patients being investigated with standard autoantibody tests for a wide variety of medical diseases and on whom adequate clinical data were not available. AKA were found in 552. The finding that 380 of these sera also produced a positive reaction in the sheep-cell agglutination test (SCAT) (table I) led to the present investigation.
We record here accumulated evidence of the prevalence of AKA in human serum, and more specifically the serum of patients with rheumatoid arthritis (RA). Group 2 comprised sera from 52 patients with non-rheumatoid diagnoses-namely, ankylosing spondylitis (8) , psoriatic arthropathy (9), scleroderma (7), keratoconjunctivitis sicca (10), osteoarthropathy (4), systemic lupus erythematosus (10) , and polymyalgia rheumatica (4). Their ages ranged from 31 to 72 years (mean 59 years).
Group 3 comprised sera from 105 healthy blood donors. These sera served as controls.
Twenty AKA-positive samples from group 1 were also tested against, mouse, monkey, and human oesophageal tissue.
Sera were tested for autoantibodies routinely at a 1/10 dilution.8 Freshly prepared cryostat sections were examined by the indirect fluorescent antibody technique9 with a fluorescein-labelled antihuman immunoglobulin G (IgG) (Wellcome Reagents Ltd). Unfixed cryostat sections of human skin and hair follicles were similarly treated with selected sera. All sera were screened with RA latex reagent (Hyland Laboratories) and positive sera titrated for rheumatoid factor using the SCAT described by Roitt and Doniach."0 An agglutination of 1/20 or more was taken as positive.
Aggregated human IgG was freshly prepared with Cohn fraction II (Sigma), as described.'1 Dilutions of AKA-positive pooled human sera were absorbed at 37°C for one hour and then kept at room temperature overnight. Next day the samples were centrifuged and assayed by immunofluorescence for AKA activity. The immunoglobulin fraction was purified from pooled AKA-positive sera by sodium sulphate precipitation (18%O w/v) and dialysed against 0-02M TRIS (trometamol)/ HCl/NaCl buffer pH 8-2. The reconstituted proteins were then passed down a column containing Ultragel (ACA 34 LKB) equilibrated with the same buffer and precalibrated with blue dextran (Pharmacia) containing purified human IgG. The purity of the eluted fractions was tested by radial immunodiffusion"2 with commercially available plates (ICL Scientific). The AKA activity of each undiluted fraction was determined as described above.
Results
Seventy-five of the sera in group 1 (580,) were AKA-positive, including eight from 24 patients who did not have rheumatoid factor (table II) . Thirty-eight SCAT-positive sera were AKA-negative. A few of the 20 AKA-positive sera tested reacted with the keratinised layer of monkey oesophagus, but none with human oesophagus, which is not keratinised. Only six of these sera, however, reacted with mouse oesophageal keratin, which is less differentiated than that of rats.'3
The keratin antibody is easily recognised in both rat oesophageal tissue (fig 1) and the keratogenous zone of human hair follicles (fig 2) . fluorescence with normal human serum. x 400 (original magnfication).
Absorption of AKA-positive sera with aggregated human IgG did not remove the antibodies. The antibody activity was shown by column chromatography to correspond to the IgG peak, and contamination with IgM could not be detected with a sensitive radial immunodiffusion method.
Discussion
The anti-keratin antibody described here gives a highly specific staining pattern with rat, mouse, and monkey oesophageal keratin and, to a less extent, with human skin. The antibody also reacts with the cortical cells of both human and non-human hair follicles. In human tissue the reaction appears to be both stronger and more specific for the keratogenous zone (fig 2) . Experimentally produced antibodies to these proteins cross-react with low-sulphur keratins in the cortical cells of the differentiating hair follicles of guinea-pigs but do not react with the keratogenous zone.6 This suggests that our reaction is different and more specific for fully differentiated keratins. Our results with the less differentiated mouse oesophageal keratin"3 and comparisons with the morphological reactions obtained in the cortical cells of mice (B J J Young; in preparation) support this interpretation.
Absorption experiments with heat-aggregated human IgG and chromatography showed that the keratin antibody is an IgG autoantibody, which is unlikely to be related to rheumatoid factor.
Thus compared with the SCAT detection of AKA appears to be highly specific for RA; only one patient with scleroderma was positive in the non-RA group. The SCAT is sensitive but not specific for RA. Kellgren et al'4 reported positive reactions in 41 0 of patients with systemic lupus erythematosus, 41%o with systemic sclerosis, 13°o with dermatomyositis, and 200O with polyarteritis nodosa, whereas specificity for RA was shown by Valkenburg et all; to increase only as the SCAT titre rises. Moreover, in random sampling in the north of England only 2600 of people with a positive SCAT result had clinical or radiological evidence of RA. 16 AKA should have a clinical value in being more specific though less sensitive than the SCAT reaction for RA.
1977.
(Accepted 5.7une 1979) SHORT REPORTS Field trial of a heat-stable measles vaccine in Cameroon Heat-labile measles vaccines are rapidly inactivated at room temperature and require a rigorously controlled cold chain for conservation without loss of potency. Recently the development of more-heat-stable measles vaccines has been reported by manufacturers. Laboratory studies of Rimevax, one such vaccine, were carried out by the manufacturer and showed that the minimum required titre (10: median tissue culture infective dose!/dose) was maintained after 14 days' storage at 37TC and after 21 days at 20'C-250C.' In order to assess this vaccine for use under field conditions in the United Republic of Cameroon we undertook the following study in Yaounde, the capital.
Methods and results
Rimevax was transferred from storage at -20'C to a covered, dark container and maintained unfrozen at room temperature for from 24 to 192 hours before its reconstitution and use. A continuous temperature monitor kept with the vaccine recorded temperatures ranging from 23-1°C to 25-4C. At 24-hour intervals eight phials of the unfrozen vaccine were removed from storage. Four phials were refrozen at -20°C for later titration and four were immediately transported, at ambient temperatures and in a dark container, to the vaccination site, where they were reconstituted with diluent at the same temperature as the vaccine. With informed consent of the parents 0 5 cm3 of the vaccine was administered subcutaneously by needle and syringe to children aged 9-24 months who had no history of measles. Vaccine was administered within 30 minutes of reconstitution; before and 30 days after immunisation capillary blood was collected on filter-paper discs from finger puncture as described by Mathews et al.2
The discs were dried for 24 hours and stored sealed with a desiccant at -20°C. Measles hemagglutination inhibition antibody determination was performed on this blood according to the techniques developed by Hierholzer and Suggs3 and Norrby.4 Vaccine virus titration was performed on the Rimevax using the method described by Peetermans.5
None of the children had a history of measles during the period of the study. Seroconversion was defined as a rise in titre from seronegative ( < 1 :10) to > 1:20; all children who failed to seroconvert were revaccinated. Out of 55 children aged 13-24 months, 53 seroconverted (96 % seroconversion rate), while out of 77 children aged 9-12 months, 69 seroconverted (rate of 90 %) ( 
